Egis Expands Portfolio with Well-Known Product Line

Egis Pharmaceuticals Plc. has acquired one of Teva Pharmaceuticals Plc.'s well-known product family for skin application, following the approval of the competition authority, the pharmaceutical manufacturer informed MTI on Monday.

According to the statement, the takeover of the distribution and promotion of the product line began on December 17, 2024, and the parties sought to ensure the continuous supply of the product to consumers.

It was recalled that Teva Pharmaceuticals Plc. decided to divest the product line in line with its global business strategy and to focus on its other global, skin-applicable, topical brands.

Egis has already marketed topical dermatological products, and the current acquisition will further expand this portfolio, strengthening the company's position in the Hungarian non-prescription market, it said.

Egis Pharmaceuticals Plc. is a pharmaceutical company with more than 110 years of history, with headquarters in Hungary and active pharmaceutical ingredient and pharmaceutical manufacturing plants.

Its activities cover all the value-adding processes of the pharmaceutical industry, from research and development to the manufacture of active ingredients and finished products, and sales.

The company's consolidated net sales for the financial year that ended on September 30 rose to HUF 245.878 billion from HUF 219.084 billion in the previous year, while its overall result for the year fell from HUF 46.045 billion to HUF 2.827 billion in the same period.

The net sales of Teva Pharmaceuticals increased from HUF 225.818 billion in 2022 to HUF 240.061 billion in 2023, while adjusted profit after tax decreased from HUF 223.724 billion to HUF 115.917 billion in that period.